Assessment of incidence of inhibitors in patients with haemophilia.
In patients with haemophilia, the development of neutralizing allo-antibodies ('inhibitors') while receiving the deficient clotting factor is relatively common during the patients' initial treatment. Among treated patients with haemophilia who do not develop inhibitors early on, the later incidence is considerably lower. Therefore, the evaluation of potential risk factors for their tendency to give rise to inhibitors is best performed separately in previously untreated and previously treated patients. We discuss potential implications of study design and analysis choices on the validity of inferences from studies assessing inhibitor incidences.
van der Bom
J G
JG
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. j.g.vanderbom@lumc.nl
ter Avest
P
P
Van den Berg
H M
HM
Psaty
B M
BM
Weiss
N S
NS
D000367:Age Factors; D019774:Blood Coagulation Factor Inhibitors / Q000037:antagonists & inhibitors*; D005169:Factor VIII / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D018570:Risk Assessment; D012307:Risk Factors
D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII